PharmaCyte Biotech (PMCB) EBITDA Yield: History & Chart

PharmaCyte Biotech, Inc.(PMCB)

Biotechnology · Las Vegas, NV

$0.43+0.04 (+10.23%)

Delayed quote: Oct 6, 2026, 1:23 PM EDT

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.

Las Vegas, NV

2 employees

pharmacyte.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joshua N. Silverman

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
PharmaCyte Biotech, Inc. (PMCB)	$4.62M	N/A	N/A	N/A	N/A
CalciMedica, Inc. (CALC)vs ›	$4.65M	N/A	N/A	N/A	N/A
Dermata Therapeutics, Inc. (DRMA)vs ›	$4.55M	N/A	N/A	N/A	N/A
Bio Green Med Solution, Inc. (BGMS)vs ›	$4.69M	N/A	N/A	N/A	N/A
Lexaria Bioscience Corp. (LEXX)vs ›	$4.83M	N/A	N/A	N/A	N/A
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.43M	N/A	2.09%	2.09%	2.09%
20/20 Biolabs Inc. (AIDX)vs ›	$4.25M	N/A	N/A	N/A	N/A
Xenetic Biosciences, Inc. (XBIO)vs ›	$5.01M	N/A	N/A	N/A	N/A
Imunon, Inc. (IMNN)vs ›	$5.13M	N/A	N/A	N/A	N/A
Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›	$5.10M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

PharmaCyte Biotech, Inc. (PMCB)

$4.62M

N/A

CalciMedica, Inc. (CALC)vs ›

$4.65M

N/A

Dermata Therapeutics, Inc. (DRMA)vs ›

$4.55M

N/A

Bio Green Med Solution, Inc. (BGMS)vs ›

$4.69M

N/A

Lexaria Bioscience Corp. (LEXX)vs ›

$4.83M

N/A

CollPlant Biotechnologies Ltd. (CLGN)vs ›

$4.43M

N/A

2.09%

20/20 Biolabs Inc. (AIDX)vs ›

$4.25M

N/A

Xenetic Biosciences, Inc. (XBIO)vs ›

$5.01M

N/A

Imunon, Inc. (IMNN)vs ›

$5.13M

N/A

Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›

$5.10M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

PMCB EBITDA Yield Metrics

PMCB Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics